1050477-31-0

1050477-31-0 structure

Name: Finerenone
Chemical Name: (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
CAS Number: 1050477-31-0
Molecular Formula: C₂₁H₂₂N₄O₃
Molecular Weight: 378.42400
Catalog: Signaling Pathways Metabolic Enzyme/Protease Mineralocorticoid Receptor
Create Date: 2016-04-08 11:30:29
Modify Date: 2024-01-02 17:20:02
Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease[1][2].

Name	(4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
Synonyms	Finerenone UNII-DE2O63YV8R

Description	Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease[1][2].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> Metabolic Enzyme/Protease >> Mineralocorticoid Receptor
In Vivo	Finerenone (BAY 94-8862) lowers albuminuria by >40% and significantly reduces systolic blood pressure (SBP) in Munich Wistar Frömter (MWF) rat[1]. Animal Model: Twelve-week-old MWF rat[1] Dosage: 10 mg/kg Administration: P.o.; daily for 4 weeks Result: Significantly reduced SBP in MWF rats; led to a significant reduction (>40%) in albuminuria in the MWF model. Animal Model: Twelve-week-old MWF rat[1] Dosage: 10 mg/kg Administration: P.o.; daily for 4 weeks Result: Significantly reduced SBP in MWF rats; led to a significant reduction (>40%) in albuminuria in the MWF model.
References	[1]. Bärfacker L, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7(8):1385-1403. [2]. González-Blázquez R, et al. Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress. Front Pharmacol. 2018;9:1131. Published 2018 Oct 9.

Molecular Formula	C₂₁H₂₂N₄O₃
Molecular Weight	378.42400
Exact Mass	378.16900
PSA	111.25000
LogP	4.27338

Hazard Codes	T+

1158522-08-7	940364-43-2
134104-43-1	131615-57-1
6906-52-1	930439-75-1
1857304-07-4	2343964-49-6
1018584-77-4	1375289-11-4